Wang Hairong, Liu Shiming, Jia Li, Chu Fengyun, Zhou Ya, He Zhixu, Guo Mengmeng, Chen Chao, Xu Lin
Special Key Laboratory of Gene Detection & Therapy of Guizhou Province, Zunyi, 563000 Guizhou China.
2Department of Immunology, Zunyi Medical College, Zunyi, 563000 Guizhou People's Republic of China.
Cancer Cell Int. 2018 Jul 13;18:101. doi: 10.1186/s12935-018-0596-x. eCollection 2018.
MicroRNAs (miRNAs), which are endogenous about 20-23 nucleotides non-coding RNAs, have been acted as post-transcriptional regulators of gene expression. Current studies demonstrated that miRNAs are promising candidates for tumor gene therapy because of their important biological functions in tumor cell proliferation, metastasis, apoptosis, and drug resistance. As an important delivery system, nanostructured lipid carriers (NLCs) have great potential in tumor gene therapy, particularly for miRNA delivery, due to low toxicity, low immunogenicity, long metabolic cycles, and easy modification. This article reviews recent research progress on NLCs for miRNA delivery in tumor gene therapy and prospective applications.
微小RNA(miRNA)是约20 - 23个核苷酸的内源性非编码RNA,其作为基因表达的转录后调节因子发挥作用。目前的研究表明,miRNA因其在肿瘤细胞增殖、转移、凋亡和耐药性方面的重要生物学功能,有望成为肿瘤基因治疗的候选者。作为一种重要的递送系统,纳米结构脂质载体(NLC)由于低毒性、低免疫原性、长代谢周期和易于修饰,在肿瘤基因治疗中,尤其是miRNA递送方面具有巨大潜力。本文综述了纳米结构脂质载体用于肿瘤基因治疗中miRNA递送的最新研究进展及其潜在应用。